Healthcare

Healthcare

CloudMD (OTC: DOCRF) to Acquire Snapclarity Inc., an Enterprise Mental Health Platform, Expanding Telehealth Offering to Include Mental Wellness

July 18, 2020 admin Comments Off on CloudMD (OTC: DOCRF) to Acquire Snapclarity Inc., an Enterprise Mental Health Platform, Expanding Telehealth Offering to Include Mental Wellness

A silent mental health crisis existed before the COVID-19 pandemic and has now been brought to the forefront as a crisis on its own. COVID 19 has created a global focus on mental and physical […]

Healthcare

Valeo Pharma Receives Approval from Health Canada for the Transfer of Commercial Rights to Ametop™

July 14, 2020 admin Comments Off on Valeo Pharma Receives Approval from Health Canada for the Transfer of Commercial Rights to Ametop™

AmetopTM commercialization to begin in July 2020 First of four Valeo products scheduled for launch this summer MONTREAL , July 13, 2020  – Valeo Pharma Inc. (VPH.CN) (“Valeo” or the “Company“), a Canadian specialty pharmaceutical company,  announced today […]

Healthcare

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

May 18, 2020 admin Comments Off on CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

VANCOUVER, Washington, May 18, 2020 — Three arms of this trial will be leronlimab, remdesivir, and leronlimab + remdesivir CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), […]

Healthcare

CytoDyn (OTC: CYDY) to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

May 15, 2020 admin Comments Off on CytoDyn (OTC: CYDY) to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

VANCOUVER, Washington, May 15, 2020– CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is […]

Healthcare

Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn (OTC: CYDY) for Drug Product Used in COVID-19 Clinical Trials

May 5, 2020 admin Comments Off on Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn (OTC: CYDY) for Drug Product Used in COVID-19 Clinical Trials

SAN DIEGO, May 5, 2020  —- Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., […]

Healthcare

CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

April 30, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, Apr 30, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

April 27, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

Company appoints Interim Chief Financial Officer VANCOUVER, Washington, Apr 27, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for […]

Healthcare

CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

April 27, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

VANCOUVER, Washington, Apr 27, 2020  — During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 […]

Healthcare

CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

April 13, 2020 admin Comments Off on CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

VANCOUVER, Washington, Apr 13, 2020  — More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more […]

Healthcare

CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

April 6, 2020 admin Comments Off on CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Fifteen (15) severely ill COVID-19 patients have been treated under an EIND; 7-day results from the first four patients are available and are very promising; 7-day results for the first 10 patients will be available […]

Healthcare

CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

March 31, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

VANCOUVER, Washington, Mar 31, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

March 31, 2020 admin Comments Off on FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]